Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges

被引：8
|
作者：
Ceresoli, Giovanni Luca [1 ]
Bonomi, Maria [1 ]
Sauta, Maria Grazia [1 ]
机构：
[1] Clin Humanitas Gavazzeni, Thorac & GU Oncol Unit, Dept Med Oncol, I-24125 Bergamo, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 07期
关键词：
Malignant pleural mesothelioma; immunotherapy; immune-checkpoint inhibitors; SINGLE-ARM; OPEN-LABEL; TREMELIMUMAB; CISPLATIN; BLOCKADE; PHASE-2; CANCER; SAFETY;
D O I：
10.1080/14737140.2016.1191951
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：673 / 675
页数：3
相关论文
共 50 条
  • [21] Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma
    Rondon, Lizbeth
    Fu, Roberto
    Patel, Manish R.
    CANCERS, 2023, 15 (11)
  • [22] Prominent Expression of the Negative Immune Checkpoint Regulator VISTA in Malignant Pleural Mesothelioma (MPM)
    Muller, Stephanie
    Zauderer, Marjorie
    Desmeules, Patrice
    Jungbluth, Achim
    Fayad, Miriam
    Frosina, Denise
    Ni, Ai
    Ladanyi, Marc
    Sauter, Jennifer L.
    MODERN PATHOLOGY, 2018, 31 : 743 - 743
  • [23] Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
    Kim, Roger Y.
    Mitra, Nandita
    Bagley, Stephen J.
    Marmarelis, Melina E.
    Haas, Andrew R.
    Rendle, Katharine A.
    Vachani, Anil
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [24] Combined Immune Checkpoint Blockade in Malignant Pleural Mesothelioma: In Vivo Validation of in Vitro Results
    Marcq, E.
    De Waele, J.
    Van Audenaerde, J.
    Jacobs, J.
    Van Loenhout, J.
    Pauwels, P.
    Smits, E.
    Van Meerbeeck, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S752 - S752
  • [25] Prominent Expression of the Negative Immune Checkpoint Regulator VISTA in Malignant Pleural Mesothelioma (MPM)
    Muller, Stephanie
    Zauderer, Marjorie
    Desmeules, Patrice
    Jungbluth, Achim
    Fayad, Miriam
    Frosina, Denise
    Ni, Ai
    Ladanyi, Marc
    Sauter, Jennifer L.
    LABORATORY INVESTIGATION, 2018, 98 : 743 - 743
  • [26] Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.
    Reuss, Joshua E.
    Sepesi, Boris
    Rolfo, Christian Diego
    Zahurak, Marianna
    Anagnostou, Valsamo
    Smith, Kellie Nicole
    Cottrell, Tricia
    Stein, Julie E.
    Illei, Peter Bela
    Taube, Janis M.
    Rosner, Gary L.
    Murray, Joseph Christopher
    Nakajima, Erica C.
    Voong, K. Ranh
    Hales, Russell K.
    Yang, Stephen
    Battafarano, Richard James
    Friedberg, Joseph
    Tsao, Anne S.
    Forde, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Use of Immune Checkpoint Inhibitors in Mesothelioma
    Patrick M. Forde
    Arnaud Scherpereel
    Anne S. Tsao
    Current Treatment Options in Oncology, 2019, 20
  • [28] Use of Immune Checkpoint Inhibitors in Mesothelioma
    Forde, Patrick M.
    Scherpereel, Arnaud
    Tsao, Anne S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (02)
  • [29] Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
    Zhang, Xuemei
    Chang, Lele
    Ma, Qian
    Zhang, Qian
    Xu, Wansu
    Li, Qingwei
    THORACIC CANCER, 2024, 15 (20) : 1590 - 1597
  • [30] Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma
    Raghav, Kanwal
    Liu, Suyu
    Overman, Michael
    Morani, Ajaykumar
    Willette, Anneleis
    Fournier, Keith
    Varadhachary, Gauri
    JAMA NETWORK OPEN, 2021, 4 (08)
12345